Effect of a single dose of pamidronate administered at the time of surgery in a rabbit posterolateral spinal fusion model.

Eur Spine J

Department of Orthopaedic Surgery, Pontificia Universidad Catolica de Chile, Marcoleta 352, Santiago, Chile.

Published: June 2010

Spinal fusion is usually performed on patients who receive bisphosphonates (BP); however, limited data on their action on spinal fusion are available. Previous studies in animal models have shown that chronic administrations of BP reduced spinal fusion rates, and only one study has shown that a single dose administration of zolendronic acid increased fusion rate. The objective of the present study was to evaluate if pamidronate (PA), which was previously demonstrated to reduce spinal fusion rate when administered continuously for 8 weeks, would increase the spinal fusion rate if administered in a single dose at the time of surgery in a rabbit model. Thirty-two New Zealand rabbits underwent an L5-L6 posterolateral intertransverse fusion with iliac crest autograft. Animals were randomized to receive either PA 3 mg/kg in a single dose immediately after surgery, or normal saline. Animals were killed 8 weeks after surgery and fusion was determined by manual palpation and radiographic analysis. Fusion healing was obtained in eight rabbits (50%) in the PA group and in four animals (25%) in the control group, p = 0.137. In a rabbit model, a single dose of PA did not decrease lumbar spinal arthrodesis consolidation rates, but it obtained a nonsignificant higher spinal fusion rate.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899989PMC
http://dx.doi.org/10.1007/s00586-010-1288-yDOI Listing

Publication Analysis

Top Keywords

spinal fusion
28
single dose
20
fusion rate
16
fusion
11
time surgery
8
surgery rabbit
8
spinal
8
rate administered
8
rabbit model
8
single
5

Similar Publications

Spondylolysis is defined as a defect or elongation in the pars interarticularis of the lumbar spine, either unilateral or bilateral. Growing children with bilateral spondylolysis may develop spondylolisthesis, i.e.

View Article and Find Full Text PDF

Background And Objectives: Safety and efficacy of IV onasemnogene abeparvovec has been demonstrated for patients with spinal muscular atrophy (SMA) weighing <8.5 kg. SMART was the first clinical trial to evaluate onasemnogene abeparvovec for participants weighing 8.

View Article and Find Full Text PDF

Paraspinal hematomas are common complications following spine surgery. In general, these hematomas are asymptomatic and resolve without issue. Unfortunately, there is a paucity of literature that describes the recurrence of these hematomas in a chronic setting.

View Article and Find Full Text PDF

Background: High-grade Isthmic Spondylolisthesis often requires surgical intervention for spinal realignment and decompression. This study describes a modified Bohlman procedure utilizing robotic-assisted navigation and a Globus SI-LOK interbody device.

Methods: A retrospective review was conducted on three patients who underwent the modified Bohlman procedure for high-grade spondylolisthesis at a single hospital between 2022 and 2023.

View Article and Find Full Text PDF

Background: In recent years, there has been a growing utilization of minimally invasive (MI) techniques, which provide the potential advantages of minimizing surgical stress, post-operative pain, and hospitalization duration. Nevertheless, the existing body of literature primarily comprises of studies conducted at a single medical site, which are of low quality and lack a comprehensive analysis of treatment techniques exclusively focused on spondylolisthesis. We conducted this systematic review and meta-analysis to compare minimally invasive surgery (MIS) and open surgery (OS) spinal fusion outcomes for the treatment of spondylolisthesis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!